<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194700</url>
  </required_header>
  <id_info>
    <org_study_id>NAI008</org_study_id>
    <secondary_id>2007-003627-20</secondary_id>
    <nct_id>NCT01194700</nct_id>
  </id_info>
  <brief_title>Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers</brief_title>
  <official_title>Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brian J Lipworth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of plastic spacers and breath actuated
      spacers on respirable drug delivery of combination steroid inhaler (Seretide/Advair) and
      whether electrostatic charge within plastic spacers has a clinically relevant impact on the
      inhaled steroid delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conventional plastic spacers are bulky and can be influenced by electrostatic charge, which
      can reduce respirable dose delivery especially when used brand new &quot;out of the box&quot;. Breath
      actuated integrated vortex spacer (Synchro-Breathe) is a compact palm sized antistatic device
      with a vortex chamber which is designed to be more patient friendly and free from the effects
      of electrostatic charge. The systemic bioavailability from the lung of inhaled fluticasone
      and salmeterol is dependent on respirable dose delivery, and hence the performance of inhaler
      devices can be quantified by measuring the degree of adrenal suppression and fall in serum
      potassium(K) as surrogates for delivered lung dose. This study attempts to compares the
      systemic bioavailability from the lung in real life conditions for Fluticasone/Salmeterol
      combination (measured in terms of relative adrenal suppression and fall in serum K) via the
      breath actuated Synchro-Breathe device, pMDI( Seretide Evohaler), and Aerochamber Plus &amp;
      Volumatic spacer used brand new &quot;out of the box&quot; in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overnight Urinary Cortisol creatinine ratio</measure>
    <time_frame>within 24 hours after study drug inhalation</time_frame>
    <description>This outcome measure evaluates the amount of cortisol being suppressed after inhaled steroid administration. This helps to assess the systemic effect of steroid inhalation and therefore the propensity for adrenal suppression which is a noted adverse effect with high dose inhaled steroids</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Potassium</measure>
    <time_frame>60 minutes post treatment</time_frame>
    <description>The serum potassium is monitored 60 minutes post study drug inhalation to assess the systemic beta-2-adrenoreceptor metabolic response. Long acting beta agonists like Salmeterol exhibit dose related reduction in serum potassium.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Evohaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Volumatic spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerochamber Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Synchro-Breathe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide 250(8puffs) via Evohaler actuator</intervention_name>
    <description>8 puffs of Seretide250/Placebo via Evohaler actuator</description>
    <arm_group_label>Evohaler</arm_group_label>
    <arm_group_label>Volumatic spacer</arm_group_label>
    <arm_group_label>Aerochamber Plus</arm_group_label>
    <arm_group_label>Synchro-Breathe</arm_group_label>
    <other_name>Advair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide 250 (8 puffs)/placebo via Volumatic spacer</intervention_name>
    <description>8 puffs of Seretide 250/placebo via volumatic spacer</description>
    <arm_group_label>Evohaler</arm_group_label>
    <arm_group_label>Volumatic spacer</arm_group_label>
    <arm_group_label>Aerochamber Plus</arm_group_label>
    <arm_group_label>Synchro-Breathe</arm_group_label>
    <other_name>Advair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide 250/placebo 8 puffs via Aerochamber Plus spacer</intervention_name>
    <description>Seretide 250/placebo 8 puffs via Aerochamber Plus</description>
    <arm_group_label>Evohaler</arm_group_label>
    <arm_group_label>Volumatic spacer</arm_group_label>
    <arm_group_label>Aerochamber Plus</arm_group_label>
    <arm_group_label>Synchro-Breathe</arm_group_label>
    <other_name>Advair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide 250/placebo via Synchro-Breathe</intervention_name>
    <description>Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device</description>
    <arm_group_label>Evohaler</arm_group_label>
    <arm_group_label>Volumatic spacer</arm_group_label>
    <arm_group_label>Aerochamber Plus</arm_group_label>
    <arm_group_label>Synchro-Breathe</arm_group_label>
    <other_name>Advair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Volunteers

          2. Male or female 18-65

          3. Informed Consent

          4. Ability to comply with the requirements of the protocol

        Exclusion Criteria:

          1. No respiratory disease

          2. Smokers

          3. Recent respiratory tract infection (2 months).

          4. Any other clinically significant medical condition such as unstable angina, acute
             myocardial infarction in the preceding 3 months, recent TIA/ CVA,that may endanger the
             health or safety of the participant, or jeopardise the protocol.

          5. Any significant abnormal laboratory result as deemed by the investigators

          6. Pregnancy, planned pregnancy or lactation

          7. Known or suspected contra-indication to any of the IMP's

          8. Concomitant use of medicines (prescribed, over the counter or herbal) that may
             interfere with the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Nair</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian J Lipworth</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Research Group, Department of cardiovascular &amp; lung biology, Division of medicine, Ninewells Hospital &amp; Medical School</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Brian J Lipworth</investigator_full_name>
    <investigator_title>Professor (Clinical) Airway allergy and COPD</investigator_title>
  </responsible_party>
  <keyword>lung bioavailability</keyword>
  <keyword>asthma</keyword>
  <keyword>seretide</keyword>
  <keyword>Spacer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

